

Elanix Biotechnologies AG: Expansion of the Management Board, election of the Chairman of the Supervisory Board

Elanix Biotechnologies AG / Key word(s): Personnel

15.02.2016 10.10

Publishing of an ad hoc announcement as per §15 pursuant to German Securities Trading Law (WpHG), transmitted by DGAP – a service of the EQS Group AG.

The issuer is responsible for the content of this announcement.

Elanix Biotechnologies AG: Expansion of the Management Board, election of the Chairman of the Supervisory Board

ELANIX Biotechnologies AG, WKN A0WMJQ, ISIN DE000A0WMJQ4 announces that the replacement members of the Supervisory Board of ELANIX Biotechnologies AG from February 5th 2016, namely Mr Matthias Gärtner, Berlin, Mr Torsten Cejka, Eisenhüttenstadt as well as Prof. Dr. Walter Blancke, Bayreuth, held an inaugural assembly on February 12th 2016.

In this assembly Mr Torsten Cejka was elected as Chairman of the Supervisory Board and Mr Matthias Gärtner was elected as vice Chairman of the Supervisory Board of ELANIX Biotechnologies AG.

Mr Tomas Svoboda, Eysins, Switzerland, will be the CEO of the Company as of February 12th 2016. Mr Svoboda counts on nearly 30 years of experience in the Life Science industry, among others at Boston Scientific, Haemonetics and Serono as well as various start-up companies in the biotech area. He will be responsible for the overall operative activities of the Elanix Group.

15.02.2016 – The DGAP distribution services include Regulatory Announcements, Corporate News / Finances and press releases. DGAP media archive at www.dgap-medientreff.de and www.dgap.de

Language: German
Company: Elanix Biotechnologies AG
Fritz-Vomfelde-Str
40547 Düsseldorf
Germany
Phone:
Fax:
E-mail:
Internet:
ISIN: DE000A0WMJQ4, DE000A0L1MM9
WKN: A0WMJQ
Stock exchange: Regulated Market in Frankfurt (General Standard);
Open Market in Berlin, Düsseldorf

End of announcement

DGAP News Service
